A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA)
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要